A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorLaNova Medicines Limited
About this trial
This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.
Eligibility criteria
Qualifiers
Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
Aged 18-80 years old (including boundary values) , male or female.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Life expectancy ≥ 3 months.
Disqualifiers
Previously received with same target therapy.
Subjects has participated in any other interventional clinical trial within 28 days prior to the first dosing of LM-2417.
Subjects with anti-tumor treatment within 21 days prior to the first dosing of LM-2417, including radiotherapy, chemotherapy, endocrine therapy, and immunotherapy, etc.
Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
Trial design
Treatments tested in this trial
- LM-2417
- Docetaxel
- Toripalimab/Tirelizumab
- Carboplatin
- Niraparib
- Lenvatinib
Treatment groups
320 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov